Title of Rule and Other Identifying Information: Disciplinary action reporting time frame. The pharmacy quality assurance commission (commission) is proposing to amend WAC 246-945-231 to clarify the time frame for pharmaceutical firms to report disciplinary action to the commission.

Hearing Location(s): On December 4, 2025, at 10:30 a.m., at the Department of Labor and Industries, 7273 Linderson Way S.W., Tumwater, WA 98501; or via Zoom at https://us02web.zoom.us/j/86309299195 or https://zoom.us/join, Webinar ID 863 0929 9195; or One-tap mobile +12532158782,,86309299195# US (Tacoma), +12532050468,,86309299195# US; or phone 1-253-215-8782 US (Tacoma), 1-253-205-0468 US.

Submit Written Comments to: Julia Katz, P.O. Box 47852, Olympia, WA 98504-7852, email PharmacyRules@doh.wa.gov, fax 360-236-2260, https://fortress.wa.gov/doh/policyreview, beginning the date and time of this filing, by November 20, 2025, at 11:59 p.m.

Assistance for Persons with Disabilities: Contact Julia Katz, phone 360-236-4946, fax 360-236-2260, TTY 711, email PharmacyRules@doh.wa.gov, by November 20, 2025.

Purpose of the Proposal and Its Anticipated Effects, Including Any Changes in Existing Rules: The commission is proposing to amend WAC 246-945-231 to clarify the time frame for pharmaceutical firms to report disciplinary action, including denial, revocation, suspension, or restriction to practice by another state, federal, or foreign authority, to the commission. The proposed rule amends WAC 246-945-231 by incorporating the reporting time frame of 30 calendar days that is already required by WAC 246-16-220 to clarify the pharmacy rule without changing its effect.

Commission staff received feedback from interested parties about challenges concerning a time frame for pharmaceutical firms credentialed by the commission to report disciplinary action by another state, federal, or foreign authority to the commission per WAC 246-945-231.

Reasons Supporting Proposal: There is currently no specified time frame for pharmaceutical firms to report disciplinary action by another state, federal, or foreign authority to the commission. Incorporating the 30-day time frame will clarify the reporting requirement is consistent with the mandatory reporting time frame already established in WAC 246-16-220. The commission is addressing feedback from interested parties that the current lack of time frame clarification poses a challenge.

Name of Agency Personnel Responsible for Drafting and Implementation: Julia Katz, 111 Israel Road S.E., Tumwater, WA 98501, 360-236-4946; Enforcement: Marlee B. O'Neill, 111 Israel Road S.E., Tumwater, WA 98501, 360-480-9108.

A cost-benefit analysis is not required under RCW 34.05.328. A cost-benefit analysis is exempt under RCW 34.05.328 (5)(b)(iv) as the proposed rule clarifies language of a rule without changing its effect.

This rule proposal, or portions of the proposal, is exempt from requirements of the Regulatory Fairness Act because the proposal:

Is exempt under RCW 19.85.025(3) as the rules only correct typographical errors, make address or name changes, or clarify language of a rule without changing its effect.

Explanation of exemptions: The amendment to WAC 246-945-231 is exempt under RCW 34.05.310 (4)(c) because it clarifies the 30-day time frame that is already required under another rule, WAC 246-16-220.

Any pharmaceutical firm credentialed by the commission must report to the commission any disciplinary action, including denial, revocation, suspension, or restriction to practice by another state, federal, or foreign authority within 30 calendar days of the determination or finding as defined in WAC 246-16-210.